文献速递肾小球疾病

IgA肾病的精准医学:前路仍长

Precision medicine in immunoglobulin A nephropathy: still a journey ahead.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

IgA肾病是最常见的原发性肾小球疾病,发病涉及遗传、免疫和环境等多因素,临床病程异质性大。尿Dickkopf-3是可预测肾功能病程的候选生物标志物,新建立的国际队列风险预测工具可估计诊断后数年肾功能下降50%的风险。支持治疗是所有患者的主要支柱,而免疫抑制治疗的附加价值尚不明确,早期风险分层和个体化治疗仍需进一步探索。

要点

  • IgA肾病病程异质性大,需早期识别进展高风险患者。
  • 尿Dickkopf-3是预测肾功能病程的有前景生物标志物。
  • 国际队列风险预测工具可估计诊断后数年肾功能下降50%风险。

核心结论

  • IgA肾病精准医学尚在探索阶段,早期风险分层和个体化治疗是未来方向。

研究设计与样本

  • 综述性文章,讨论IgA肾病精准医学的现状与挑战。

主要发现

  • 尿Dickkopf-3是预测肾功能病程的有前景候选生物标志物。
  • 基于国际IgA肾病患者队列建立的风险预测工具,可在诊断时结合生物特征、临床、组织学及治疗信息,估计数年肾功能下降50%的风险。
  • 支持治疗是所有IgA肾病患者的主要支柱,而进展风险患者的附加免疫抑制治疗价值尚不明确。

临床怎么用

  • 诊断时利用风险预测工具进行个体化风险分层,以辅助治疗策略选择。
  • 所有IgA肾病患者均应接受综合支持治疗。

局限性

  • 精准医学在IgA肾病中的应用仍处于探索阶段,早期风险分层和个体化治疗选择仍在讨论中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease worldwide and since its first description extensive research has identified a number of key central pathogenetic contributors, including genetic, immunological and environmental factors. Along with its multifaceted pathophysiology, the clinical presentation of IgAN varies, ranging from mild forms with only minor urinary findings and preserved renal function to cases that rapidly progress to end-stage renal disease. Because of this, early identification of patients at risk for a progressive course is urgently needed. The search for valid and easily accessible biomarkers showed urinary Dickkopf-3 as a promising candidate to predict the course of kidney function. In addition, a recently established IgAN risk prediction tool derived from an international cohort of IgAN patients allows estimation of the risk of a 50% loss of kidney function over several years upon diagnosis. This might serve as a significant tool to individually predict the course of renal function by combining biometric, clinical, histological and treatment information at the time of diagnosis. Today there is no doubt that a comprehensive supportive treatment regimen is the main pillar for all IgAN patients. The value of an additional immunosuppressive treatment in IgAN patients at risk for disease progression is less clear. Early risk stratification and individualized therapies would be desirable for IgAN patients to facilitate the choice of treatment strategies, which is still a matter of ongoing discussion.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Seikrit C, Rauen T, Stamellou E, et al. Precision medicine in immunoglobulin A nephropathy: still a journey ahead. Nephrol Dial Transplant. 2021. PMID: 34153983. doi:10.1093/ndt/gfab032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。